Origimm raises funds from a selected group of individuals who join as stakeholders of the company. In addition to the indication of trust, support and enthusiasm, the received funds will help Origimm intensify its research and development efforts to successfully reach the upcoming project milestone: the selection of lead antigen candidates for a P. acnes vaccine.